Other · developed by 35Pharma Inc., a GSK company
HS135 is a drug studied in heart failure with preserved ejection fraction and pulmonary hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06581159 | Phase 1 | Heart Failure With Preserved Ejection Fraction | Terminated | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Heart Failure With Preserved Ejection FractionPulmonary Hypertension
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →